The primary objective of this study is to evaluate the safety and efficacy of once-daily topical application of CLS001 1%, 1.75% and 2.5% topical gel compared to vehicle topical gel in subjects with inflammatory acne vulgaris

Inclusion Criteria:

• Male or non-pregnant female subjects with facial acne vulgaris, 12 years of age or older.
• Subjects with ≥20 inflammatory facial lesions (papules, pustules) inclusive of the nose, with a maximum of 9 inflammatory pustules.
• An Investigator's Global Assessment (IGA) of Moderate (3) or Severe (4)

Exclusion Criteria:

• Subjects with acne conglobate, acne fulminans, and secondary acne (chloracne, drug-induced acne, polycystic ovarian syndrome, etc.)
• Subjects with greater that 75 facial non-inflammatory lesions (open and/or closed comedones; excluding the nose)
• Subjects with more than 2 facial nodulocystic lesions